Holen Sie sich die Stockscreener-App
26.54
0.90%
-0.24
Handel nachbörslich:
26.50
-0.04
-0.15%
Schlusskurs vom Vortag:
$26.78
Offen:
$26.86
24-Stunden-Volumen:
1.03M
Relative Volume:
1.37
Marktkapitalisierung:
$1.53B
Einnahmen:
$681.88M
Nettoeinkommen (Verlust:
$122.63M
KGV:
12.58
EPS:
2.11
Netto-Cashflow:
$220.18M
1W Leistung:
-2.71%
1M Leistung:
-20.08%
6M Leistung:
-8.45%
1J Leistung:
-23.76%
1-Tages-Spanne:
$25.97
$26.86
1-Wochen-Bereich:
$25.97
$27.48
52-Wochen-Spanne:
$25.97
$41.61
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Vergleichen Sie HRMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
26.54 | 1.54B | 681.88M | 122.63M | 220.18M | 2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
Does Harmony Biosciences Holdings Inc. show high probability of reboundGlobal Markets & Technical Buy Zone Confirmations - newser.com
Can Harmony Biosciences Holdings Inc. hit a new high this monthJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Using AI based signals to follow Harmony Biosciences Holdings Inc.July 2025 News Drivers & Daily Technical Forecast Reports - newser.com
Custom watchlist performance reports with Harmony Biosciences Holdings Inc.Inflation Watch & Community Shared Stock Ideas - newser.com
Harmony Biosciences Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges - Markets Mojo
Harmony Biosciences stock hits 52-week low at $26.26 By Investing.com - Investing.com Nigeria
What analysts say about Harmony Biosciences Holdings Inc stockEarnings Volatility Patterns & Amplify Gains With Picks - earlytimes.in
Harmony Biosciences (NASDAQ:HRMY) Hits New 1-Year LowWhat's Next? - MarketBeat
Robeco Institutional Asset Management B.V. Takes $1.48 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Top 3 Health Care Stocks That Are Preparing To Pump In Q4 - Sahm
Harmony Biosciences Forms Death Cross, Signaling Bearish Trend Ahead - Markets Mojo
Is Harmony Biosciences (HRMY) the Oversold Biotech Stock to Buy Now? - MSN
Using Bollinger Bands to evaluate Harmony Biosciences Holdings Inc.Weekly Trade Report & Weekly Breakout Watchlists - newser.com
Understanding Harmony Biosciences Holdings Inc.’s price movementOil Prices & Low Drawdown Investment Strategies - newser.com
What drives Harmony Biosciences Holdings Inc stock priceSector Leadership Analysis & Master Stock Selection - earlytimes.in
Harmony Biosciences’ Fragile X Trial Falls Short but Offers Key Insights - MyChesCo
Exit strategy if you’re trapped in Harmony Biosciences Holdings Inc.July 2025 Trends & Stock Portfolio Risk Management - newser.com
Harmony Biosciences Hits New 52-Week Low at $26.26 - Markets Mojo
Harmony Biosciences (HRMY): Assessing Valuation After RECONNECT Trial Disappointment for ZYN002 in Fragile X Syndrome - Yahoo Finance
H.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 Setback - MSN
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Surpass Estimates - MSN
10 Best Low Priced Growth Stocks to Buy Now - Insider Monkey
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Rating of “Buy” from Analysts - Defense World
Q3 EPS Estimate for Harmony Biosciences Boosted by Analyst - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Wall Street Zen Downgrades Harmony Biosciences (NASDAQ:HRMY) to Hold - MarketBeat
Harmony Biosciences Holdings Inc Stock Analysis and ForecastAutomated Trading Signals & Free Trend Following Techniques - Early Times
Harmony Biosciences Hits 52-Week Low at $26.35 Amid Market Struggles - Markets Mojo
HC Wainwright Has Positive Estimate for HRMY Q2 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Medtronic (MDT) - The Globe and Mail
Harmony Biosciences (NASDAQ:HRMY) Given New $35.00 Price Target at Mizuho - Defense World
Mizuho lowers Harmony Biosciences stock price target to $35 after trial setback By Investing.com - Investing.com Nigeria
Mizuho lowers Harmony Biosciences stock price target to $35 after trial setback - Investing.com Canada
Harmony Biosciences stock price target lowered to $55 at H.C. Wainwright - Investing.com Australia
Harmony Biosciences stock price target lowered to $55 at H.C. Wainwright By Investing.com - Investing.com South Africa
Deutsche Bank Maintains Harmony Biosciences Holdings (HRMY) Buy Recommendation - Nasdaq
Harmony Biosciences Hits Day Low of $26.61 Amid Price Pressure - Markets Mojo
Harmony Biosciences: Cannabinoid Fragile X Fail Merits Rating Downgrade (NASDAQ:HRMY) - Seeking Alpha
Mizuho Issues Pessimistic Forecast for Harmony Biosciences (NASDAQ:HRMY) Stock Price - MarketBeat
Mizuho Lowers Price Target for Harmony Biosciences (HRMY) to $35 - GuruFocus
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal - The Globe and Mail
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Harmony Biosciences Holdings Inc-Aktie (HRMY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kapadia Sandip | CHIEF FINANCIAL OFFICER |
Aug 15 '25 |
Sale |
36.50 |
21,573 |
787,378 |
0 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):